参考文献/References:
[1] Mills KT,Bundy JD,KellyTN,et al.Global disparities of hypertension prevalence and control[J].Circulation,2016,134(6):441-450.
[2]RossierBC,BochudM,Devuyst O.The hypertension pandemic: an evolutionary perspective[J].Physiology,2017,32(2):112-125.
[3] Brook RD,Appel LJ,Rubenfire M,et al.Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association[J].Hypertension,2013,61(6):1360-1383.
[4] Saxena T,Ali AO,Saxena M.Pathophysiology of essential hypertension: an update[J].Expert Rev Cardiovasc Ther,2018,16(12):879-887.
[5] 付士辉,李玉龙,骆雷鸣,等.高血压基础研究现状与进展[J].心血管病学进展,2019,40(9):1202-1205.
[6] Bartel DP.Metazoan microRNAs[J].Cell,2018,173(1):20-51.
[7] Hill JM,Zhao Y,Bhattacharjee S,et al.MiRNAs and viroids utilize common strategies in genetic signal transfer[J].Front Mol Neurosci,2014,7:10.
[8] Fromm B,Billipp T,Peck LE,et al.A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome[J].Annu Rev Genet,2015,49(1):213-242.
[9] Gangwar RS,Rajagopalan S,Natarajan R,et al.Noncoding RNAs in cardiovascular disease:pathological relevance and emerging role as biomarkers and therapeutics[J].Am J Hypertens,2018,31(2):150-165.
[10] 朱凤,范恒,刘星星.miR-155在炎症性肠病中的免疫作用机制研究进展[J].世界华人消化杂志,2019,27(17):1070-1075.
[11] Huang Y,Huang C,Zhang B,et al.Association of circulating miR-155 expression level and inflammatory markers with white coat hypertension[J].J Hum Hypertens,2020,34(5):397-403.?
[12] Youssef HMG,Marei ES.Association of microRNA-210 and microRNA-155 with severity of preeclampsia[J].Pregnancy Hypertens,2019,17:49-53.
[13] Huang Y,Chen J,Zhou Y,et al.Circulating miR155 expression level is positive with blood pressure parameters: Potential markers of target-organ damage[J].Clin Exp Hypertens,2016,38(3):331-336.
[14] Klimczak D,Kuch M,Pilecki T,et al.Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension[J].J Am Soc Hypertens,2017,11(12):831-841.
[15] Touyz RM,Alves-Lopes R,Rios FJ,et al.Vascular smooth muscle contraction in hypertension[J].Cardiovasc Res,2018,114(4):529-539.
[16] Nemecz M,Alexandru N,Tanko G,et al.Role of microRNA in endothelial dysfunction and hypertension[J].Curr Hypertens Rep,2016,18(12):87.
[17] Sun H,Zeng D,Li R,et al.Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase[J].Hypertension,2012,60(6):1407-1414.
[18] Xu D,Liao R,Wang X,et al.Effects of miR-155 on hypertensive rats via regulating vascular mesangial hyperplasia[J].Eur rev med pharmaco,2018,22(21):7431-7438.
[19] Choi S,Park M,Kim J,et al.TNF-α elicits phenotypic and functional alterations of vascular smooth muscle cells by miR-155-5p–dependent down-regulation of cGMP-dependent kinase 1[J].J Biol Chem,2018,293(38):14812-14822.
[20] Park M,Choi S,Kim S,et al.NF-κB-responsive miR-155 induces functional impairment of vascular smooth muscle cells by downregulating soluble guanylyl cyclase[J].Exp Mol Med,2019,51(2):1-12.
[21] Sun H,Zhao M,Liu T,et al.Salusin-β induces foam cell formation and monocyte adhesion in human vascular smooth muscle cells via miR155/NOX2/NFκB pathway[J].Sci Rep,2016,6(1):2014-2026.
[22] Wu N,Ye C,Zheng F,et al.MiR155-5p inhibits cell migration and oxidative stress in vascular smooth muscle cells of spontaneously hypertensive rats[J].Antioxidants,2020,9(3):204.
[23] Ren X,Tong Y,Qiu Y,et al.MiR155-5p in adventitial fibroblasts-derived extracellular vesicles inhibits vascular smooth muscle cell proliferation via suppressing angiotensin-converting enzyme expression[J].J Extracell Vesicles,2020,9(1):1698795.
[24] Zheng L,Xu C,Chen W,et al.MicroRNA-155 regulates angiotensinⅡtype 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts[J].Biochem Bioph Res Co,2010,400(4):483-488.
[25] Cheng W,Liu T,Jiang F,et al.microRNA-155 regulates angiotensinⅡtype 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women[J].Int J Mol Med,2011,27(3):393-399.
[26] Dupont JJ,Mccurley A,Davel AP,et al.Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging[J].JCI Insight,2016,1(14):e88942.
[27] 李杰,覃智芳,颜彦,等.SHR大鼠肾脏去交感神经与主动脉miRNA相关性分析[J].东南大学学报(医学版),2018,37(1):6-11.
[28] Wang L,Zhang Y,Lin Q,et al.CXCL1–CXCR2 axis mediates angiotensinⅡ-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration[J].Eur Heart J,2018,39(20):1818-1831.
[29] Yuan Y,Wang J,Chen Q,et al.Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling[J].BBA-Mol Basis Dis,2019,1865(6):1421-1427.
[30] Heymans S,Corsten MF,Verhesen W,et al.Macrophage microRNA-155 promotes cardiac hypertrophy and failure[J].Circulation,2013,128(13):1420-1432.
[31] Lu C,Chen B,Chen C,et al.CircNr1h4 regulates the pathological process of renal injury in salt‐sensitive hypertensive mice by targeting miR-155-5p[J].J Cell Mol Med,2019,24(2):1700-1712.
[32] Vandenwijngaert S,Ledsky CD,Agha O,et al.MicroRNA-425 and microRNA-155 cooperatively regulate atrial natriuretic peptide expression and cGMP production[J].PLoS One,2018,13(4):e196697.
[33] Yang J,Si D,Zhao Y,et al.S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension[J].Biomed Pharmacother,2019,114:108799.
[34] Amara VR,Surapaneni SK,Tikoo K.Metformin attenuates cardiovascular and renal injury in uninephrectomized rats on DOCA-salt: Involvement of AMPK and miRNAs in cardioprotection[J].Toxicol Appl Pharmacol,2019,362:95-104.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]